# A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Source: https://onco.cc/trials/nct07271667/  
OnCo record `nct07271667` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zanubrutinib in chronic lymphocytic leukaemia, run by Curis, Inc., now recruiting.

## Summary

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies is a phase 2 interventional study registered as NCT07271667 by Curis, Inc., with 108 participants planned, started 2026-04-23 and due to reach its primary completion in 2027-11. Interventions recorded: Emavusertib and Zanubrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07271667
- Phase: 2
- Setting: A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
- Sponsor: Curis, Inc.
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT07271667: https://clinicaltrials.gov/study/NCT07271667

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Emavusertib](https://onco.cc/drugs/emavusertib/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [Curis](https://onco.cc/companies/curis/)

---
JSON: https://onco.cc/api/v1/entities/nct07271667.json